Artivion | CRY - Cash And Equivalent


Artivion reported $77.32M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Accuray USD 41.29M 22.05M Dec/2025
AngioDynamics USD 41.64M 14.26M Sep/2025
Artivion USD 77.32M 21.55M Jun/2026
AtriCure USD 167.79M 21.62M Jun/2026
Baxter International USD 2.15B 133M Jun/2026
Becton, Dickinson and Co. USD 708M 105M Jun/2026
Boston Scientific USD 539M 914M Jun/2026
Edwards Lifesciences USD 2.9B 500M Jun/2026
Inogen USD 106.48M 2.79M Sep/2025
Integra LifeSciences USD 214.42M 22.39M Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Mesa Laboratories USD 28.98M 8.55M Dec/2025
Orthofix International USD 103.81M 16.47M Jun/2026
Pfizer USD 976M 727M Jun/2026
ResMed USD 1.47B 191.28M Jun/2026
Stryker USD 3.39B 513M Jun/2026
Tandem Diabetes Care USD 62.82M 116.51M Jun/2026
Teleflex USD 300.16M 9.25M Jun/2026
Terumo JPY 280.49B 63.34B Mar/2026
Trinity Biotech USD 5.14M 3.8M Dec/2025